Tag Archives: T-cell therapy

April, 2018

  • 12 April

    FDA Lifts Clinical Hold on US Studies of Bellicum’s BPX-501

    HOUSTON, April 11, 2018 (GLOBE NEWSWIRE) — Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that the U.S. Food and Drug Administration has lifted the clinical hold on studies of BPX-501 in the U.S. The decision follows consultation with the FDA and agreement on amendments …

January, 2017

September, 2016

August, 2016

February, 2016

  • 2 February

    GSK and Adaptimmune Expand Immunotherapy Collaboration

    GlaxoSmithKline plc (LSE/NYSE: GSK) and Adaptimmune Therapeutics plc (Nasdaq: ADAP), a leader in the use of T-cell receptor (TCR) engineered T-cell therapy to treat cancer, today announced that the companies have expanded the terms of their strategic collaboration agreement to accelerate Adaptimmune’s lead clinical cancer programme, an affinity enhanced T-cell …